Characteristics | Multiple metastases | |||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
HRs (95%CI) | p-value | HRs (95%CI) | p-value | |
Stage at diagnosis | ||||
 I + II | 1.00 | 0.076 |  |  |
 III | 1.695 (0.946–3.030) |  |  |  |
Adjuvant chemotherapy | ||||
 Yes | 1.00 | 0.613 |  |  |
 No | 1.151 (0.667–1.989) |  |  |  |
Age at recurrence | ||||
 < 50y | 1.00 |  |  |  |
 ≥ 50y | 0.807 (0.366–1.782) | 0.596 |  |  |
CEA/CA15–3 serum level | ||||
 Normal | 1.00 |  |  |  |
 High | 1.337 (0.688–2.595) | 0.391 |  |  |
DFI | ||||
 < 2 years | 3.229 (1.768–5.895) | < 0.001 | 3.082 (1.669–5.694) | < 0.001 |
 ≥ 2 years | 1.00 |  |  |  |
Initial therapy for reccurence | ||||
 Endocrine therapy | 1.00 | 0.524 |  |  |
 Chemotherapy | 1.187 (0.700–2.013) |  |  |  |
Metastatic organ site | ||||
 Bone | 0.769 (0.455–1.301) | 0.328 |  |  |
 Lymph node | 1.334 (0.790–2.255) | 0.281 |  |  |
 Lung | 0.757 (0.452–1.266) | 0.289 |  |  |
 Liver | 2.915 (1.689–5.025) | < 0.001 | 3.145 (1.802–5.495) | < 0.001 |
 Pleura | 1.406 (0.781–2.530) | 0.256 |  |  |
 Brain | 2.532 (1.078–5.952) | 0.033 | 3.289 (1.355–7.937) | 0.008 |